

Agnese Latorre

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7232532/publications.pdf>

Version: 2024-02-01

31
papers

863
citations

567144

15
h-index

477173

29
g-index

31
all docs

31
docs citations

31
times ranked

1347
citing authors

#	ARTICLE	IF	CITATIONS
1	An Invasive Disease Event-Free Survival Analysis to Investigate Ki67 Role with Respect to Breast Cancer Patients' Age: A Retrospective Cohort Study. <i>Cancers</i> , 2022, 14, 2215.	1.7	4
2	Downstream Signaling of Inflammasome Pathway Affects Patients' Outcome in the Context of Distinct Molecular Breast Cancer Subtypes. <i>Pharmaceuticals</i> , 2022, 15, 651.	1.7	3
3	Robustness Evaluation of a Deep Learning Model on Sagittal and Axial Breast DCE-MRIs to Predict Pathological Complete Response to Neoadjuvant Chemotherapy. <i>Journal of Personalized Medicine</i> , 2022, 12, 953.	1.1	15
4	Predicting of Sentinel Lymph Node Status in Breast Cancer Patients with Clinically Negative Nodes: A Validation Study. <i>Cancers</i> , 2021, 13, 352.	1.7	33
5	A Clinical Decision Support System for Predicting Invasive Breast Cancer Recurrence: Preliminary Results. <i>Frontiers in Oncology</i> , 2021, 11, 576007.	1.3	21
6	A Roadmap towards Breast Cancer Therapies Supported by Explainable Artificial Intelligence. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 4881.	1.3	24
7	Chemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer. <i>Journal of Oncology</i> , 2020, 2020, 1-17.	0.6	11
8	Efficacy and safety of lenvatinib in an elderly patient with metastatic papillary thyroid carcinoma and cardiological comorbidity: a case report. <i>Future Oncology</i> , 2019, 15, 27-33.	1.1	1
9	Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group) Tj ETQq1 1 0.784314 rgBf /Over		
10	A multicenter REtrospective observational study of first-line treatment with PERTuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. <i>Cancer Biology and Therapy</i> , 2019, 20, 192-200.	1.5	30
11	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 474-485.	5.1	59
12	Efficacy and safety of eribulin in taxane-refractory patients in the "real world". <i>Future Oncology</i> , 2017, 13, 971-978.	1.1	13
13	Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 587-594.	1.1	9
14	FISH testing of HER2 immunohistochemistry 1+ invasive breast cancer with unfavorable characteristics. <i>Oncology Letters</i> , 2016, 12, 3115-3122.	0.8	13
15	Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 669-678.	1.2	14
16	A broad Italian experience with eribulin mesylate in metastatic breast cancer patients: The ESEMPIo study. <i>Journal of Clinical Oncology</i> , 2015, 33, e11539-e11539.	0.8	3
17	Rapid tumor shrinkage with lapatinib plus capecitabine in a patient with massive liver involvement. <i>Tumori</i> , 2013, 99, 278e-81e.	0.6	0
18	A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011, 30, 39.	3.5	20

#	ARTICLE	IF	CITATIONS
19	A Multicenter Phase II Randomized Trial of Docetaxel/Gemcitabine versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Gruppo Oncologico Italia Meridionale Study. <i>Oncology</i> , 2011, 81, 230-236.	0.9	8
20	Liposomal-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: a phase II multicentric study. <i>Annals of Oncology</i> , 2007, 18, vi66-vi69.	0.6	24
21	Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of β ² -tubulins. <i>International Journal of Cancer</i> , 2007, 120, 2078-2085.	2.3	132
22	Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale). <i>Annals of Oncology</i> , 2006, 17, vii15-vii17.	0.6	31
23	Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. <i>Annals of Oncology</i> , 2005, 16, iv14-iv19.	0.6	127
24	A Phase I Study of Capecitabine in Combination with Vinorelbine in Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2003, 4, 138-141.	1.1	19
25	Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer. <i>British Journal of Cancer</i> , 2003, 88, 491-495.	2.9	8
26	Amifostine as chemoprotectant in metastatic breast cancer patients treated with doxorubicin. <i>Oncology Reports</i> , 2003, 10, 163.	1.2	2
27	Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. <i>European Journal of Cancer</i> , 2001, 37, 364-368.	1.3	151
28	Mitoxantrone, L-Leucovorin and 5-Fluorouracil: An Effective and Well Tolerated First-Line Treatment for Advanced Breast Cancer. <i>Tumori</i> , 1999, 85, 60-64.	0.6	0
29	Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum.. <i>Journal of Clinical Oncology</i> , 1997, 15, 3208-3213.	0.8	30
30	Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma. <i>European Journal of Cancer</i> , 1996, 32, 730-733.	1.3	25
31	Long-term Subcutaneous Recombinant Interleukin-2 as Maintenance Therapy: Biological Effects and Clinical Implications. <i>Cancer Biotherapy</i> , 1995, 10, 195-203.	0.6	18